Daratumumab plus VRd in Japanese transplant‑ineligible/deferred NDMM patients: Japanese subgroup of the CEPHEUS trial
Suzuki K, et al.
International Journal of Hematology
March 2026
Authors and Affiliates
Kenshi Suzuki1 · Morio Matsumoto2 · Hiroyuki Takamatsu3 · Hiroshi Kosugi4 · Tadakazu Kondo5 ·
Tomoaki Fujisaki6 · Thierry Facon7 · Sonja Zweegman8 · Miku Ito9 · Chika Sakai9 · Satoshi Kanai9 ·
Tomohiko Nakatogawa9 · Melissa Rowe10 · Robin Carson11 · Saad Z. Usmani12
Department of Hematology, Japanese Red Cross Medical
Center, 4‑1‑22 Hiroo, Shibuya‑ku, Tokyo 150‑8935, Japan
2 Department of Hematology, NHO Shibukawa Medical
Center, Gunma, Japan
3 Department of Hematology, Kanazawa University Hospital,
Ishikawa, Japan
4 Department of Hematology, Ogaki Municipal Hospital, Gifu,
Japan
5 Department of Hematology, Kobe City Medical Center
General Hospital, Hyogo, Japan
6 Department of Hematology, Matsuyama Red Cross Hospital,
Ehime, Japan
7 Service des Maladies du sang, Hôpital Claude Huriez, Centre
Hospitalier Universitaire de Lille, Lille, France
8 Department of Hematology, Cancer Center Amsterdam, Vrije
Universiteit Medical Center, Amsterdam, The Netherlands
9 Johnson & Johnson, Tokyo, Japan
10 Johnson & Johnson, High Wycombe, UK
11 Johnson & Johnson, PA, USA
12 Memorial Sloan Kettering Cancer Center, New York, NY,
USA